# Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

> **NCT06917495** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shandong University** · enrollment: 300 (estimated)

## Conditions studied

- Mild Spinal Tuberculosis

## Interventions

- **DRUG:** Rifampin
- **DRUG:** Isoniazid
- **DRUG:** Rifapentine (RPT)
- **DRUG:** Moxifloxacin
- **DRUG:** Pyrazinamide
- **DRUG:** Ethambutol

## Key facts

- **NCT ID:** NCT06917495
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-05
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06917495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06917495, "Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06917495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*